Alnylam Pharmace. Stock
€270.70
Your prediction
Alnylam Pharmace. Stock
Alnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Pros and Cons of Alnylam Pharmace. in the next few years
Pros
Cons
Performance of Alnylam Pharmace. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alnylam Pharmace. | 0.410% | -3.128% | 1.050% | 12.720% | 19.256% | 89.852% | 99.970% |
| Ironwood Pharmaceuticals | -3.050% | 3.968% | 15.929% | -88.992% | -84.405% | -94.491% | -92.682% |
| Arrowhead Pharmaceuticals Inc. | -0.960% | 10.278% | 14.972% | -39.259% | -15.301% | -63.249% | -61.440% |
| Novocure Ltd | 0.230% | -0.199% | -4.135% | -8.611% | -48.249% | -79.217% | -70.509% |
Comments
News
Alnylam Stock: FDA Approves Amvuttra for Rare Heart Disease
Alnylam Pharmaceuticals has secured a significant victory with the FDA's approval to expand Amvuttra's (vutrisiran) use for treating transthyretin amyloidosis cardiomyopathy (ATTR-CM), a rare and
